Galidor, pills 100mg 50pcs

Composition

of 1 tab. :

– bencyclane fumarate 100 mg

Auxiliary substances:

potato starch,

polyvinyl acetate,

magnesium stearate,

carbomer 934 P,

sodium carboxymethyl starch (type A),

colloidal anhydrous silicon dioxide,

talc.

Pharmacological action

Pharmaceutical group:

antispasmodic agent.

Pharmaceutical action:

Halidor is a myotropic antispasmodic with a pronounced vasodilating effect. The vasodilating effect of bencyclane is mainly due to its ability to block calcium channels, antiserotonin action, and to a lesser extent – with the blockade of sympathetic ganglia.

Bencyclane can cause dose-dependent suppression of Na+ / K+-dependent ATPase and platelet and red blood cell aggregation, as well as an increase in red blood cell elasticity. These effects are mainly observed in peripheral vessels, coronary arteries, and brain vessels.

In addition, bencyclane has an antispasmodic effect on the visceral muscles (gastrointestinal tract, urinary tract, respiratory organs).

The drug causes a slight increase in heart rate. Its weak tranquilizing effect is also known.

Indications

Vascular diseases: – peripheral vascular diseases – Raynaud’s disease, other diseases with acrocyanosis and vascular spasm, as well as chronic obliterating arterial diseases— – cerebral vascular diseases: in the complex therapy of acute and chronic cerebral ischemia. To eliminate spasm of internal organs: — gastrointestinal diseases-gastroenteritis of various etiologies (especially infectious), infectious and inflammatory colitis, functional diseases of the large intestine, tenesmus, postoperative flatulence, cholecystitis, cholelithiasis, condition after cholecystectomy, motor disorders in Oddi sphincter dyskinesia, peptic ulcer of the stomach and duodenum (as part of combination therapy);- urological syndromes: spasms and tenesmus of the bladder, concomitant therapy of urolithiasis (in combination with analgesics for renal colic);Preparation for instrumental research methods in urology (for solution for intravenous and intramuscular use).

Use during pregnancy and lactation

Adequate and strictly controlled clinical studies on the use of Galidor® during pregnancy and lactation have not been conducted.

Therefore, use of the drug to patients in the first trimester of pregnancy is not recommended. If it is necessary to use the drug during lactation, the question of stopping breastfeeding during treatment should be decided.

Data from preclinical studies did not reveal any embryotoxic or teratogenic effects.

Contraindications

-severe respiratory failure— – severe renal failure;- severe liver failure;— decompensated heart failure; – acute myocardial infarction— – AV block; – paroxysmal supraventricular or acute ventricular tachycardia— – epilepsy and other forms of spasmophilia— – recent hemorrhagic stroke;- traumatic brain injury (within the last 12 months);— pregnancy; – lactation period (breastfeeding);- children and adolescents under 18 years of age (insufficient experience of use);- hypersensitivity to the components of the drug Galidor.

Side effects

From the digestive system: dry mouth, abdominal pain, feeling full, nausea, vomiting, decreased appetite, diarrhea, increased activity of hepatic transaminases in blood serum.

From the central nervous system: anxiety, dizziness, headache, gait disorders, tremor, sleep disorders, insomnia, memory disorders; rarely-transient confusion, epileptiform seizures, hallucinations in elderly patients; in isolated cases-symptoms of focal damage to the central nervous system.

From the cardiovascular system: sometimes – atrial and ventricular tachyarrhythmia (especially when co-administered with other proarrhythmogenic drugs).

Other: general malaise, weight gain, leukopenia, allergic reactions; rarely-thrombophlebitis with intravenous use.

Interaction

When used concomitantly, Halidor ® increases the depressing effect on the central nervous system of anesthesia and sedatives.

When used concomitantly with sympathomimetics, the risk of developing tachycardia, atrial and ventricular tachyarrhythmias increases. With the simultaneous use of Halidor and drugs that reduce the level of potassium in the blood (including diuretics, cardiac glycosides), and quinidine, proarrhythmogenic effects can be summed up.

When used concomitantly with digitalis preparations, the risk of arrhythmia increases with an overdose of cardiac glycosides.

When using Halidor concomitantly with beta-blockers, it may be necessary to select the dose of beta-blockers due to the opposite chronotropic effects (negative for beta-blockers and positive for bencyclane).

When used concomitantly with calcium channel blockers and other antihypertensive drugs, their effect may be enhanced.

When Halidor is used concomitantly with drugs that cause side effects in the form of spasmophilia, these effects can be summed up.

When used concomitantly with acetylsalicylic acid, it is possible to increase inhibition of platelet aggregation.

How to take, course of use and dosage

Vascular diseases:

Inside, Galidor® is prescribed 100 mg 3 times a day. within 2-3 months. The maximum daily dose for oral use is 400 mg. The interval between courses is 2-3 months.

The drug can also be used in the form of intravenous infusions in a daily dose of 200 mg, divided into 2 injections. Before the infusion,100 mg (4 ml) of the drug is diluted in 100-200 ml of isotonic sodium chloride solution and administered intravenously for 1 hour 2 times / day.

To eliminate spasm of internal organs:

Inside, Galidor® is prescribed at a dose of 100-200 mg once, but not more than 400 mg / day. For maintenance therapy,100 mg is prescribed 3 times a day. for 3-4 weeks, then 100 mg 2 times / day. The duration of treatment is determined individually depending on the disappearance of symptoms of the disease and, as a rule, does not exceed 1-2 months. In acute cases, Halidor® is administered intravenously slowly at a dose of 100-200 mg (4-8 ml) or intramuscularly at a dose of 50 mg (2 ml). Before intravenous use, the required amount of the solution is diluted with an isotonic sodium chloride solution to 10-20 ml. The course of treatment is 2-3 weeks, followed by the transfer of the patient, if necessary, to take the drug Galidor® inside.

Overdose

Symptoms: increased heart rate, decreased blood pressure, collapse, impaired renal function, urinary incontinence, drowsiness, anxiety, in severe cases-epileptiform seizures. A significant overdose can cause tonic and clonic seizures.

Allergic reactions.

Treatment: performing symptomatic therapy. When taking a large number of tablets, gastric lavage should be performed. Benzodiazepines are recommended for the treatment of seizures. The specific antidote is not known. There are no data on the possible elimination of bencyclane by dialysis.

Special instructions

When Halidor is co-administered with drugs that cause hypokalemia, cardiac glycosides, or drugs that inhibit myocardial function, the daily dose of Halidor should not exceed 150-200 mg.

When used parenterally, the injection site should be changed, since the drug can cause damage to the vascular endothelium and thrombophlebitis.

It is necessary to refrain from parenteral use of the drug to patients with severe cardiovascular or respiratory insufficiency, predisposed to collapse, as well as with prostatic hypertrophy and urinary retention (the degree of delay increases with relaxation of the bladder muscles).

With prolonged use of Halidor, systematic (at least 1 time in 2 months) laboratory studies of the rheological properties of blood are recommended.

Influence on the ability to drive motor vehicles and manage mechanisms

At the beginning of the course of treatment, patients should take special care when driving vehicles and other potentially dangerous activities.

Form of production

Halidor tablets are white or grayish-white in color, round, flat, chamfered, with the inscription “HALIDOR” on one side, with a faint characteristic smell.

Storage conditions

At a temperature of 15-25 °C

Shelf life

5 years

Active ingredient

Bencyclane

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Purpose

For adults as directed by your doctor

Indications

Urolithiasis, Colitis, Cholecystitis, Raynaud’s disease, Spasm of the gastrointestinal tract, Gastric ulcer and duodenal ulcer, Cholelithiasis